TITLE

An Institutional Sepsis Collaborative: The Impact of a Continuous Quality Improvement Process

AUTHOR(S)
B., McLellan; R., Mooney; G., Boleski
PUB. DATE
April 2008
SOURCE
Critical Care Nurse;Apr2008, Vol. 28 Issue 2, pe11
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
An abstract of the article "An Institutional Sepsis Collaborative: The Impact of a Continuous Quality Improvement Process," by B. McLellan, R. Mooney et al. is presented.
ACCESSION #
31609377

 

Related Articles

  • Sweet inspiration. Dajer, Tony // Discover;Aug97, Vol. 18 Issue 8, p36 

    Presents the author's experience as a physician who treated sepsis by securing a patient's airway. Problems in performing an intubation for the patient; Resistance from the patient's respiratory region adding to the procedure's difficulty; Satisfaction over the successful performance of the...

  • Hospital's sepsis program initiative boosts safety.  // Healthcare Risk Management;Mar2008, Vol. 30 Issue 3, p32 

    The article reports on the clinical program established by the hospital team at the Barnes-Jewish Hospital which focuses on the diagnosis and treatment of sepsis among patient in St. Louis, Missouri.

  • Why sepsis trials fail. Bone, Roger C. // JAMA: Journal of the American Medical Association;8/21/96, Vol. 276 Issue 7, p565 

    Opinion. Suggests that few critical conditions in medicine are as paradoxical as the events which occur during sepsis. Proposition that the development of sepsis has several stages, each of which has a pro-inflammatory and an anti-inflammatory component; Speculation as to why sepsis trails can...

  • Correction.  // Clinical Journal of Oncology Nursing;Aug2014, Vol. 18 Issue 4, p382 

    No abstract available.

  • Innovation in sepsis management.  // American Journal of Health-System Pharmacy;2/15/2002, Vol. 59 Issue 4, pS30 

    Presents a continuing education questionnaire on sepsis management. Epidemiology of sepsis; Criteria for severe sepsis; Organisms most commonly associated with sepsis as causative pathogens.

  • Recombinant human activated protein C in severe sepsis. Mann, Henry J. // American Journal of Health-System Pharmacy;2/15/2002, Vol. 59 Issue 4, pS19 

    Protein C, a naturally occurring vitamin K-dependent serine protease in the blood, remains inactive until exposed to the thrombin-thrombomodulin complex. This change between the inactive and active forms occurs constantly in humans and serves to balance the coagulation cascade. APC functions in...

  • Management challenge with drotrecogin alfa (activated). Vanscoy, Gordon J. // American Journal of Health-System Pharmacy;2/15/2002, Vol. 59 Issue 4, pS23 

    Clinical trial results for drotrecogin alfa (activated) are discussed in terms of potential effect on morbidity and total cost of care. Interdisciplinary collaboration is crucial for improving care in health systems; teamwork has been shown to improve outcomes in intensive care and reduce costs....

  • Drotecogin alfa sustains survival long-term in severe sepsis patients.  // Formulary;Dec2002, Vol. 37 Issue 12, p622 

    Reports on the use of drotecogin alfa for the treatment of sever sepsis. Results of clinical trials; Effectiveness in reducing patient mortality; Common side effects of the drug.

  • Management of Sepsis. Perel, Azriel; Segal, Eran // New England Journal of Medicine;3/15/2007, Vol. 356 Issue 11, p1178 

    The article presents a letter to the editor in response to the article "Management of sepsis," by J. A. Russell in the October 19, 2006 issue.

  • Management of Sepsis. Khurana, Aman; Vinayek, Namita // New England Journal of Medicine;3/15/2007, Vol. 356 Issue 11, p1178 

    The article presents a letter to the editor in response to the article "Management of sepsis," by J. A. Russell in the October 19, 2006 issue.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics